$BBNX insider trading
Over the last 12 months, Beta Bionics insiders reported no purchases and 39 sales totaling $3.6M across SEC Form 4 filings. 51% of those filings were made under pre-arranged 10b5-1 trading plans.
- Bought · 12m
- — 0 events
- Sold · 12m
- $3.6M 39 events
- Events · 12m
- 39 Form 4 filings, grouped
- Insiders · 12m
- 8 distinct reporters
- 10b5-1 share
- 51% of events, not dollars
All insider trades
Scroll the table sideways for price, value and marks.
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Sep 3, 2026 | Saint SeanPresident & CEO · O·D | ▼ Sale | 5,641 | $20.08 | $113K | -1.4% | plan |
| Sep 2, 2026 | Russell Steven JonChief Medical Officer · O | ▼ Sale | 4,221 | $19.11 | $81K | -2.4% | — |
| Sep 2, 2026 | Saint SeanPresident & CEO · O·D | ▼ Sale | 16,867 | $19.11 | $322K | -4% | — |
| Sep 2, 2026 | Feider StephenChief Financial Officer · O | ▼ Sale | 6,675 | $19.11 | $128K | -4% | — |
| Sep 2, 2026 | Mensinger MikeChief Product Officer · O | ▼ Sale | 4,375 | $19.11 | $84K | -2.4% | — |
| Sep 2, 2026 | Hopman MarkChief Commercial Officer · O | ▼ Sale | 5,327 | $19.11 | $102K | -4.1% | — |
| Jun 29, 2026 | Feider StephenChief Financial Officer · O | ▼ Sale | 10,000 | $17.04 | $170K | -5.7% | plan · 2 tranches |
| Jun 24, 2026 | Hopman MarkChief Commercial Officer · O | ▼ Sale | 1,258 | $15.01 | $19K | -1% | plan |
| Jun 24, 2026 | Jones ChristyD | ▼ Sale | 1,406 | $15 | $21K | -5.1% | plan |
| Jun 4, 2026 | Hopman MarkChief Commercial Officer · O | ▼ Sale | 275 | $12.31 | $3K | -0.2% | plan |
| Jun 4, 2026 | Jones ChristyD | ▼ Sale | 2,811 | $14 | $39K | -9.3% | plan |
| Jun 2, 2026 | Mensinger MikeChief Product Officer · O | ▼ Sale | 4,378 | $12.61 | $55K | -2.3% | — |
| Jun 2, 2026 | Hopman MarkChief Commercial Officer · O | ▼ Sale | 5,329 | $12.61 | $67K | -3.9% | — |
| Jun 2, 2026 | Russell Steven JonChief Medical Officer · O | ▼ Sale | 4,222 | $12.61 | $53K | -2.4% | — |
| Jun 2, 2026 | Feider StephenChief Financial Officer · O | ▼ Sale | 6,676 | $12.61 | $84K | -3.9% | — |
| Jun 2, 2026 | Saint SeanPresident & CEO · O·D | ▼ Sale | 16,872 | $12.61 | $213K | -3.9% | — |
| May 21, 2026 | Jones ChristyD | ▼ Sale | 1,998 | $9.95 | $20K | -13.1% | plan |
| May 21, 2026 | Lezack AdamD | ▼ Sale | 1,000 | $9.95 | $10K | -8% | plan |
| Mar 4, 2026 | Hopman MarkChief Commercial Officer · O | ▼ Sale | 353 | $11.57 | $4K | -0.3% | plan |
| Mar 2, 2026 | Russell Steven JonChief Medical Officer · O | ▼ Sale | 1,026 | $12.36 | $13K | -0.6% | — |
| Mar 2, 2026 | Saint SeanPresident & CEO · O·D | ▼ Sale | 3,384 | $12.36 | $42K | -0.8% | — |
| Mar 2, 2026 | Feider StephenChief Financial Officer · O | ▼ Sale | 1,428 | $12.36 | $18K | -0.8% | — |
| Mar 2, 2026 | Mensinger MikeChief Product Officer · O | ▼ Sale | 1,064 | $12.36 | $13K | -0.6% | — |
| Mar 2, 2026 | Hopman MarkChief Commercial Officer · O | ▼ Sale | 834 | $12.36 | $10K | -0.6% | — |
| Jan 6, 2026 | Mensinger MikeChief Product Officer · O | ▼ Sale | 2,200 | $30.1 | $66K | -2.7% | plan |
| Jan 2, 2026 | Feider StephenChief Financial Officer · O | ▼ Sale | 20,000 | $29.53 | $591K | -31.9% | plan |
| Jan 2, 2026 | Mensinger MikeChief Product Officer · O | ▼ Sale | 7,800 | $29.61 | $231K | -8.6% | plan · 2 tranches |
| Dec 4, 2025 | Hopman MarkChief Commercial Officer · O | ▼ Sale | 2,917 | $30.27 | $88K | -2.1% | plan · late · 2 tranches |
| Dec 2, 2025 | Russell Steven JonChief Medical Officer · O | ▼ Sale | 1,025 | $29.34 | $30K | -0.6% | late |
| Dec 2, 2025 | Saint SeanPresident & CEO · O·D | ▼ Sale | 3,278 | $29.34 | $96K | -3.2% | — |
| Dec 2, 2025 | Feider StephenChief Financial Officer · O | ▼ Sale | 1,427 | $29.34 | $42K | -3.2% | — |
| Dec 2, 2025 | Mensinger MikeChief Product Officer · O | ▼ Sale | 1,063 | $29.34 | $31K | -1.2% | — |
| Dec 1, 2025 | Lezack AdamD | ▼ Sale | 1,406 | $29.55 | $42K | -14.3% | plan · 2 tranches |
| Dec 1, 2025 | Palasis MariaD | ▼ Sale | 1,406 | $29.55 | $42K | -14.3% | plan · 2 tranches |
| Oct 31, 2025 | Lezack AdamD | ▼ Sale | 1,406 | $26.87 | $38K | -12.5% | plan · 2 tranches |
| Oct 31, 2025 | Palasis MariaD | ▼ Sale | 1,406 | $26.91 | $38K | -12.5% | plan · 2 tranches |
| Oct 3, 2025 | Feider StephenChief Financial Officer · O | ▼ Sale | 4,982 | $21.69 | $108K | -10.2% | plan · 2 tranches |
| Oct 1, 2025 | Feider StephenChief Financial Officer · O | ▼ Sale | 15,018 | $20.76 | $312K | -25.4% | plan · 2 tranches |
| Sep 8, 2025 | Feider StephenChief Financial Officer · O | ▼ Sale | 9,900 | $21.13 | $209K | -18.4% | plan |
| Sep 5, 2025 | Hopman MarkChief Commercial Officer · O | ▼ Sale | 18,229 | $20.34 | $371K | -36.9% | plan · 2 tranches |
| Sep 5, 2025 | Feider StephenChief Financial Officer · O | ▼ Sale | 100 | $21 | $2K | -0.2% | plan |
| Sep 2, 2025 | Saint SeanPresident & CEO · O·D | ▼ Sale | 3,359 | $18.86 | $63K | -3.2% | — |
| Sep 2, 2025 | Russell Steven JonChief Medical Officer · O | ▼ Sale | 1,015 | $18.86 | $19K | -1.4% | — |
| Sep 2, 2025 | Mensinger MikeChief Product Officer · O | ▼ Sale | 1,089 | $18.86 | $21K | -1.2% | — |
| Sep 2, 2025 | Hopman MarkChief Commercial Officer · O | ▼ Sale | 848 | $18.86 | $16K | -2.5% | — |
| Sep 2, 2025 | Feider StephenChief Financial Officer · O | ▼ Sale | 1,462 | $18.86 | $28K | -3.2% | — |
| Aug 22, 2025 | Feider StephenChief Financial Officer · O | ▼ Sale | 4,413 | $17.01 | $75K | -8.8% | plan |
| Aug 19, 2025 | Hopman MarkChief Commercial Officer · O | ▼ Sale | 16,158 | $16.61 | $268K | -32.1% | plan |
| Aug 19, 2025 | Feider StephenChief Financial Officer · O | ▼ Sale | 5,587 | $17.03 | $95K | -10.9% | plan |
Every $BBNX filing on this page is one API call away
The same Form 4 data over REST or MCP, already grouped into events with the plan flag and the dollar value read. A free key does 100 calls a day and needs no card. Prefer email? Beta Bionics filings can reach your inbox instead.
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. This page shows open-market activity: purchases (code P), sales (S) and dispositions back to the issuer (D). Scheduled compensation events such as stock grants and option exercises are also filed on Form 4 but carry no trading signal, so they are not shown and counts here can be lower than the raw EDGAR filing total. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $BBNX feed.